Alnylam Pharmaceuticals, Inc. (ALNY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $219.72. The rating moved from Overbought to Oversold on October 1, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$219.72
• Last changeMoved from Overbought to Oversold on October 1, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Alnylam Pharmaceuticals, Inc. is positioned as a leader in RNAi therapeutics with commercial products and a pipeline that supports continued revenue expansion. The company’s platform and partner relationships provide competitive advantages and de-risk later-stage assets, but the stock remains sensitive to clinical outcomes, regulatory review, and payer-driven pricing pressure. Near-term market caution and sector-specific policy developments introduce volatility, while sustained clinical and commercial execution could drive meaningful upside over the next month.

Key factors

• Leading RNAi platform with multiple commercial-stage products and a diversified pipeline that supports medium-term revenue growth potential.
• Established commercialization capabilities and partner collaborations that help de-risk late-stage assets and broaden market access.
• Favorable investor interest in select specialty biotech and late-stage biologics, providing sector-level valuation support despite broader risk-off moves.
• Current macro environment is cautious but lacks major new policy shocks; limited near-term market catalysts could mute volatility and allow fundamentals to reassert.
• Recent therapeutic approvals in the broader biotech space validate innovation pathways and create positive clinical readthroughs for platform companies.

Risks

• Policy and payer pressure (e.g., Medicare drug-price negotiation and IRA-related dynamics) that could compress pricing and access for high-cost therapies.
• Clinical or regulatory setbacks for pipeline assets that would materially damage growth expectations.
• Manufacturing, supply-chain or delivery challenges particular to complex RNAi medicines could disrupt sales or increase costs.
• Intensifying competition from alternative modalities (e.g., ASOs, gene editing, biologics) and combination therapies that could erode market share or pricing power.
• Broader market risk-off sentiment and reduced liquidity that can disproportionately impact specialty biotech valuations and fundraising capacity.

Latest MarketMoodz coverage

• Alnylam Taps AI Partner Inceptive Nucleics in Up-to-$2B Deal2026-06-04
• Alnylam deal lifts Tenaya; milestone-heavy collaboration signals pipeline potential2026-03-05

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.